85.7 F
San Fernando
Thursday, Mar 28, 2024
Array

Camarillo Biotech Gets Funding

Immpact Bio USA, a biotech startup focused on treatment for solid tumors, closed its Series A financing round at $18 million on Tuesday. The Camarillo company was founded in 2017 in an Israeli incubator, with the core of its technology stemming from research conducted by two professors, Gideon Gross and Zelig Eshhar. The technology, commonly known as CAR-T therapies, involves engineered T-cell therapeutics. White blood cells, or T-cells, are removed from the patient’s body, modified in a lab to attack cancer cells, and are infused into the body to seek out and destroy cancer cells in the same patient. “We have built a world-class team and a promising pipeline to realize Prof. Gross’ vision of targeting loss-of-gene features of solid tumors,” Dr. Rick Kendall, chief executive of Immpact, said in a statement. “We look forward to working with our investors to advance this pipeline and make the company a success.” The company received money from OrbiMed, Johnson & Johnson Innovation – JJDC; Takeda Ventures; RM Global Partners Biopharma Investment Fund; Novartis Venture Fund; Bukwang Pharmaceutical; Hayan Health Networks; and JVC Investment Partners.

Featured Articles

Related Articles